CVS Health (NYSE:CVS) Director Larry Robbins Sells 1,983,538 Shares

CVS Health Corporation (NYSE:CVS) Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the sale, the director directly owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Larry Robbins also recently made the following trade(s):

• On Thursday, May 21st, Larry Robbins sold 370,462 shares of CVS Health stock. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90.
• On Wednesday, May 20th, Larry Robbins sold 1,018,000 shares of CVS Health stock. The stock was sold at an average price of $93.82, for a total value of $95,508,760.00.

CVS Health Price Performance

CVS stock traded up $0.07 during trading on Thursday, hitting $93.35. The company had a trading volume of 6,478,498 shares, compared to its average volume of 8,694,289. The company has a fifty day moving average price of $79.69 and a two-hundred day moving average price of $78.87. CVS Health Corporation has a fifty-two week low of $58.50 and a fifty-two week high of $98.43. The company has a market cap of $119.11 billion, a P/E ratio of 41.12, a P/E/G ratio of 0.92 and a beta of 0.60. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same period last year, the business earned $2.25 earnings per share. The business’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Glenview Capital publicly praised CVS Health’s progress, saying its concentrated position has returned 80% since May 2024 and highlighting the company’s ongoing turnaround, which may reinforce bullish investor sentiment. Glenview Capital Issues Statement on CVS Health
• Positive Sentiment: CVS also continued to announce community-focused initiatives, including senior affordable housing in New Jersey and programs supporting military families and maternal mental health, which may modestly support its reputation but are unlikely to move the stock on their own. CVS Health, Diocese of Camden, and The Walters Group Unite to Bring Senior Affordable Housing to Williamstown, New Jersey
• Neutral Sentiment: Additional company-newsroom items on maternal mental health, military support, and Aetna Better Health’s food-access program are positive from a branding standpoint, but they appear mostly promotional and have limited direct financial impact. Aetna Better Health of Louisiana Collaborates With Goodr To Launch Mobile Food Market and Chronic Care Program
• Negative Sentiment: Two hospital systems accused CVS of profiting from a “secret pricing scheme” tied to the federal 340B drug discount program, with combined alleged damages above $60 million. The lawsuits add legal, financial, and reputational risk, which could weigh on the shares. CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment

Hedge Funds Weigh In On CVS Health

A number of large investors have recently modified their holdings of CVS. Swiss RE Ltd. acquired a new stake in shares of CVS Health in the 4th quarter valued at $26,000. Sankala Group LLC acquired a new stake in shares of CVS Health in the 4th quarter valued at $28,000. Caitong International Asset Management Co. Ltd increased its stake in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 281 shares during the period. Mcguire Capital Advisors Inc. acquired a new stake in shares of CVS Health in the 4th quarter valued at $28,000. Finally, Ares Financial Consulting LLC acquired a new position in CVS Health during the 4th quarter valued at about $29,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on CVS. Morgan Stanley raised their price objective on shares of CVS Health from $93.00 to $106.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Wells Fargo & Company boosted their target price on CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. JPMorgan Chase & Co. boosted their target price on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. HSBC boosted their target price on CVS Health from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Tuesday, May 5th. Finally, Robert W. Baird raised their target price on CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Twenty-two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $98.68.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.